Αποτελέσματα Αναζήτησης
10 Ιαν 2024 · For HER2-positive MBC, if trastuzumab deruxtecan is unavailable, use trastuzumab emtansine; if unavailable, capecitabine and lapatinib; if unavailable, trastuzumab and/or chemotherapy (hormonal therapy alone for HR-positive MBC). Additional information is available at www.asco.org/resource-stratified-guidelines.
19 Αυγ 2021 · Current Personalized Treatments for Breast Cancer: Strengths and Weaknesses. The current strategies of treatment are principally based on the tumor progression and BC molecular subtypes in order to offer the most personalized treatment for BC patients. The algorithm of BC treatment is represented in Figure 2.
20 Οκτ 2023 · For non-metastatic breast cancer, surgery-based treatment is the standard management, and chemotherapy-based preoperative systemic therapy can reduce tumor volume of the breast, making breast conservation possible, and decreasing the need for axillary lymph node dissection (ALND). 2 Systemic treatment remains the preferred option for metastatic ...
11 Ιουν 2018 · The SIO guideline addressed the use of integrative therapies to manage symptoms and adverse effects during or after breast cancer treatment.
2 Ιουν 2021 · The combination of trastuzumab and pertuzumab and a single-agent chemotherapeutic should be the standard first-line treatment for most patients with HER2-positive advanced breast cancer.
13 Φεβ 2023 · In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy was effective both in advanced and early setting phase...
24 Μαρ 2021 · Numerous conventional treatments have shown the ability to extend survival in the adjuvant setting, such as trastuzumab (anti-HER2) and chemotherapy in breast cancer 32, apalutamide in...
